Compositions comprising bacterial strains
The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
1. A method of treating a condition mediated by the Th17 pathway in a subject, comprising:
administering to the subject a therapeutically effective amount of a pharmaceutical composition that contains a single Parabacteroides bacterial strain that comprises a 16s rRNA gene sequence with:
(a) at least 96% sequence identity to the sequence of SEQ ID NO:1,
(b) at least 97% sequence identity to the sequence of SEQ ID NO:2,
(c) at least 97% sequence identity to the sequence of SEQ ID NO:3,
(d) at least 97% sequence identity to the sequence of SEQ ID NO:4,
(e) at least 97% sequence identity to the sequence of SEQ ID NO:5,
(f) at least 97% sequence identity to the sequence of SEQ ID NO:6, or
(g) at least 97% sequence identity to the sequence of SEQ ID NO:9, as determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62,
wherein said bacterial strain is live and viable; and a pharmaceutically acceptable excipient, diluent, or carrier;
wherein said single Parabacteroides bacterial strain is lyophilized, wherein the single Parabacteroides bacterial strain is present in an amount that comprises from about 1×10 3 to about 1×10 11 CFU/g of the single Parabacteroides bacterial strain with respect to a total weight of the pharmaceutical composition; and wherein said pharmaceutical composition is in solid dose tablet or capsule form.
2. The method of claim 1 , wherein the bacterial strain comprises a 16s rRNA gene sequence with at least 99.9% sequence identity to the sequence shown in SEQ ID NO:9.
3. The method of claim 1 , wherein the bacterial strain is of the species Parabacteroides distasonis.
4. The method of claim 1 , wherein the administering results in a reduction of at least one cytokine of the Th17 pathway that comprises IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, IL-17F, IFN-γ, IL-10, IL-6, or TNFα.
5. The method of claim 1 , wherein the subject has a condition that comprises uveitis, multiple sclerosis, an arthritis, neuromyelitis optica, psoriasis, systemic lupus erythematosus, celiac disease, an asthma, allergic asthma, neutrophilic asthma, chronic obstructive pulmonary disease (COPD), scleritis, vasculitis, Behcet's disease, atherosclerosis, atopic dermatitis, emphysema, periodontitis, allergic rhinitis, and allograft rejection.
6. The method of claim 5 , wherein the condition is uveitis; and wherein the administering results in a reduction in retinal damage in uveitis.
7. The method of claim 5 , wherein the condition is asthma; and wherein the administering results in a reduction in neutrophilia or eosinophilia.
8. The method of claim 5 , wherein the condition is arthritis, wherein the arthritis comprises osteoarthritis, psoriatic arthritis, spondyloarthritis, ankylosing spondylitis, and juvenile idiopathic arthritis.
9. The method of claim 1 , wherein the condition mediated is not ulcerative colitis, colitis, Crohn's disease, irritable bowel disease, or rheumatoid arthritis.
10. A pharmaceutical composition that contains:
a single Parabacteroides bacterial strain that comprises a 16s rRNA gene sequence with:
(a) at least 96% sequence identity to the sequence of SEQ ID NO:1,
(b) at least 97% sequence identity to the sequence of SEQ ID NO:2,
(c) at least 97% sequence identity to the sequence of SEQ ID NO:3,
(d) at least 97% sequence identity to the sequence of SEQ ID NO:4,
(e) at least 97% sequence identity to the sequence of SEQ ID NO:5,
(f) at least 97% sequence identity to the sequence of SEQ ID NO:6, or
(g) at least 97% sequence identity to the sequence of SEQ ID NO:9,
as determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62, wherein said single Parabacteroides bacterial strain is live and viable; and
a pharmaceutically acceptable excipient, diluent, or carrier;
wherein said single Parabacteroides bacterial strain is lyophilized, wherein the single Parabacteroides bacterial strain is present in an amount that comprises from about 1×10 3 to about 1×10 11 CFU/g of the single Parabacteroides bacterial strain with respect to a total weight of the pharmaceutical composition; and wherein said pharmaceutical composition is in solid dose tablet or capsule form.
11. The pharmaceutical composition of claim 10 , wherein the single Parabacteroides bacterial strain comprises a 16s rRNA gene sequence with at least 99.9% sequence identity to the sequence shown in SEQ ID NO:9 as determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62.
12. The pharmaceutical composition of claim 10 , wherein the single Parabacteroides bacteria strain has a Sau3AI DNA restriction pattern that is the same as a Sau3AI DNA restriction pattern for the Parabacteroides distasonis strain MRX005 deposited as NCIMB 42382 as determined by amplified ribosomal DNA restriction analysis; and
wherein administration of said bacterial strain in a Collagen II stimulated mouse model results in a reduction in a level of IL-6, IL-10, IL-17A, IFN-γ, or TNF-α.
13. The pharmaceutical composition of claim 10 , wherein the single Parabacteroides bacterial strain is of the species Parabacteroides distasonis.
14. The pharmaceutical composition of claim 10 , wherein the single Parabacteroides bacterial strain is the Parabacteroides distasonis strain MRX005 deposited as NCIMB 42382.
15. The pharmaceutical composition of claim 10 , wherein at least 50% of the single Parabacteroides bacterial strain as measured by an amount of CFU, remains viable after about 1 year of storage when the pharmaceutical composition is stored in a closed container at 25° C. at 95% relative humidity.
16. The pharmaceutical composition of claim 10 , wherein the single Parabacteroides bacteria strain is present in an amount that comprises from about 1×10 6 to about 1×10 11 CFU/g of the single Parabacteroides bacterial strain with respect to a total weight of the pharmaceutical composition.
17. The pharmaceutical composition of claim 10 , wherein the single Parabacteroides bacterial strain totally or partially colonises the intestine when administered to a subject.
18. The pharmaceutical composition of claim 10 , wherein the single Parabacteroides bacterial strain comprises a 16s rRNA gene sequence with at least 99% sequence identity to the sequence shown in SEQ ID NO:9 as determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62.
19. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is encapsulated.
20. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition comprises the 16s rRNA gene sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:9.